When you buy a generic drug, you expect it to work just like the brand-name version-same active ingredients, same results, way cheaper. But behind that simple promise is a global legal battle shaped by a 30-year-old trade deal called TRIPS. It’s not just about patents on paper. It’s about whether a child in Malawi can get HIV medicine, whether a diabetic in India can afford insulin, or whether a cancer patient in Brazil can access treatment without waiting years for a patent to expire. The TRIPS agreement didn’t just change rules-it changed lives.
What TRIPS Actually Does
The TRIPS Agreement, which stands for Trade-Related Aspects of Intellectual Property Rights, was created in 1994 and became binding in 1995. It’s part of the World Trade Organization (WTO) rules, and every country that belongs to the WTO has to follow it. Before TRIPS, many developing countries didn’t even allow patents on medicines. They could copy drug formulas as long as they used a different manufacturing process. That’s how countries like India became the pharmacy of the developing world-making low-cost versions of life-saving drugs.
TRIPS changed all that. It forced every member country to grant 20-year patents on medicines from the date of filing. No more process patents. No more legal loopholes. If a drug is patented anywhere in the world, it’s protected everywhere. That meant companies could stop generic makers from producing cheaper versions-even if the original drug was sold at prices too high for most people to afford.
And it wasn’t just about patents. TRIPS also introduced something called data exclusivity. That means regulatory agencies can’t approve a generic version based on the original company’s clinical trial data for five to ten years-even after the patent expires. So even if the patent is gone, the generic drug still can’t enter the market. This creates a double layer of monopoly: one from the patent, another from the data rules.
The Real Cost: Prices Soar
The numbers don’t lie. A 2001 study in the Journal of the American Medical Association found that in developing countries, the price of patented drugs jumped by over 200% after TRIPS was implemented. In Brazil, when they started making generic antiretrovirals for HIV, the U.S. threatened trade sanctions. In South Africa, 40 pharmaceutical companies sued the government in 1998 for trying to import cheaper generics. The lawsuit was dropped only after global protests.
India’s shift from process to product patents in 2005 led to price increases of 300% to 500% for some cancer drugs, according to a Lancet Oncology study. A drug that cost $100 a month before 2005 suddenly cost $500. For families living on $2 a day, that wasn’t just expensive-it was deadly.
And it’s not just about old drugs. Newer medicines, especially for rare diseases or HIV second-line treatments, are now priced at $300 to $600 per patient per year. Compare that to the $75 per year for first-line HIV drugs today-thanks to generic competition in countries that found ways around the rules. The gap isn’t just economic. It’s moral.
Flexibilities in the Law-But Who Can Use Them?
TRIPS isn’t completely rigid. It has escape hatches. Article 31 lets governments issue compulsory licenses-allowing someone else to make a patented drug without the company’s permission. This is legal under international law. But there’s a catch: the license must be used mostly for the domestic market. So if you’re a small country with no drug factories, you can’t import generics made in India or Brazil. You’re stuck.
In 2003, the WTO tried to fix this with the so-called “Paragraph 6 Solution.” It allowed countries without manufacturing capacity to import generics made under compulsory license. Sounds fair, right? In practice, it was a nightmare. The paperwork was endless. Legal teams had to be hired. Governments had to prove they were in a public health emergency. By 2016, only one shipment of malaria medicine had been sent using this rule. One. That’s not a solution. That’s a glitch.
Thailand and Brazil were the only countries that successfully used compulsory licensing between 2001 and 2010. Both were pressured by the U.S. and pharmaceutical lobbies. Thailand was told its actions would harm trade relations. Brazil was threatened with sanctions. The message was clear: even when the law allows it, power doesn’t.
TRIPS Plus: The Hidden Rules
Even worse than TRIPS itself are the “TRIPS Plus” rules hidden in bilateral trade deals. The U.S., EU, and other rich countries don’t stop at TRIPS-they demand more. In free trade agreements, they push for:
- Patent term extensions beyond 20 years
- 10-year data exclusivity
- Blocking generic approval even if the patent is invalid
- Restrictions on compulsory licensing
For example, the EU-Vietnam Free Trade Agreement (2020) requires eight years of data exclusivity-longer than TRIPS allows. The U.S. has included these clauses in 85% of its trade deals since 2000. These aren’t accidental. They’re designed to delay generics as long as possible.
By 2020, 147 of 151 developing countries had adopted TRIPS-style patent laws. In 1995, it was only 60. The global shift was complete. And the result? The Access to Medicine Foundation found that 65% of low-income countries now face delays in approving generics because of patent linkage rules-rules that go beyond TRIPS.
The Human Impact: Who Gets Left Behind?
Behind every statistic is a person. A mother in rural Kenya who can’t afford her child’s asthma inhaler. A man in Nigeria who skips his HIV pills because he can’t pay. A woman in Peru who can’t get the new hepatitis C cure because it’s still under patent. These aren’t hypotheticals. These are daily realities.
The Global Fund reports that since 2000, antiretroviral prices dropped from $10,000 per patient per year to $75-because of generics. But that drop only happened in places where governments had the will to use compulsory licenses, where local manufacturers existed, and where international pressure didn’t stop them. Most countries didn’t get that chance.
Meanwhile, pharmaceutical companies point to innovation. They say strong patents are needed to fund new drugs. And yes, 73% of new medicines since 2000 came from companies in countries with strong IP laws. But here’s the thing: 90% of those drugs were for conditions that affect rich countries. Only 13 of 1,223 new drugs approved between 1975 and 1997 were for tropical diseases. That’s not innovation for everyone. That’s innovation for profit.
What Changed After COVID?
In October 2020, India and South Africa proposed a temporary waiver of TRIPS protections for vaccines, tests, and treatments during the pandemic. Over 100 countries supported it. The U.S., EU, and Switzerland resisted. After months of pressure, a limited waiver was agreed upon in June 2022. It allowed some countries to produce and export COVID-related products without patent permission.
It sounds like progress. But the waiver only applied to vaccines and treatments for the pandemic. It didn’t fix the core problem. It didn’t touch cancer drugs, diabetes meds, or HIV treatments. And it was temporary. The system still works the same way for everything else.
Meanwhile, the Medicines Patent Pool-a nonprofit created in 2010-has negotiated voluntary licenses for 16 HIV drugs, 6 hepatitis C drugs, and 4 TB drugs. They’ve reached 17.4 million people. That’s real progress. But it’s not a system. It’s a patchwork. It depends on companies choosing to cooperate. And they don’t always.
The Way Forward
TRIPS was sold as a balanced system. But in practice, it tilted hard toward corporate profits. The flexibilities exist-but they’re buried in legal jargon, blocked by political pressure, and too complex for most countries to use.
What’s needed isn’t more loopholes. It’s reform. Countries need to:
- Stop accepting TRIPS Plus clauses in trade deals
- Strengthen public health safeguards in patent laws
- Build local generic manufacturing capacity
- Use compulsory licensing without fear of retaliation
- Push for permanent, broad TRIPS waivers for essential medicines
Generics aren’t a threat to innovation. They’re a check on greed. When a drug costs $1,000 a pill and a generic version costs $10, the choice isn’t about science-it’s about justice. And the law should serve people, not patents.
Does TRIPS ban generic drugs?
No, TRIPS doesn’t ban generic drugs. It requires countries to grant 20-year patents on medicines, which delays generics. But it allows exceptions like compulsory licensing, where governments can authorize generic production for public health needs. The problem isn’t the law-it’s how it’s enforced and the extra restrictions added by rich countries through trade deals.
Why do some countries still make cheap generics?
Countries like India, Brazil, and South Africa used to allow process patents, meaning they could make cheaper versions of drugs by using different manufacturing methods. Even after TRIPS, they found legal ways to produce generics-through compulsory licensing, patent challenges, or by waiting for patents to expire. India, for example, still produces 20% of the world’s generic drugs because it built strong regulatory systems and resisted pressure to fully lock down its market.
Can a country import generics from another country under TRIPS?
It’s possible, but extremely difficult. The 2007 WTO amendment allows countries without manufacturing capacity to import generics made under compulsory license elsewhere. But the process requires complex paperwork, legal reviews, and approval from both the exporting and importing country. Only one shipment of malaria medicine has been sent this way since 2007. Most countries can’t afford the legal costs or political risk.
Are TRIPS rules the same for vaccines and regular medicines?
Legally, yes. But after the COVID-19 pandemic, the WTO agreed to a temporary waiver allowing countries to produce and export COVID vaccines and treatments without patent permission. This was the first major change to TRIPS in decades. However, the waiver only applied to pandemic-related products and expired in 2023. For all other medicines-like cancer drugs or diabetes treatments-TRIPS rules remain unchanged.
What’s the difference between a patent and data exclusivity?
A patent protects the chemical formula of a drug for 20 years. Data exclusivity protects the clinical trial data used to prove the drug is safe and effective. Even if the patent expires, regulators can’t approve a generic until the data exclusivity period ends-usually 5 to 10 years. So a drug might be off-patent, but still blocked from generics because no one can use the original company’s research data to get approval.